open access
"....The inference is that progestins, compounds widely used for a variety
of clinical indications, could also be valuable in the management of
ovarian cancer, the most lethal of all gynecological malignancies.....
"The present study not only identifies the PR-FOXO1 axis as a potential
therapeutic target in ovarian cancer, but also helps to explain why
expression of PR is a prognostic marker for ovarian cancer associated
with longer progression-free survival. Similarly, this study provides a
mechanistic explanation for why pregnancy, which is associated with high
circulating progesterone levels, and the use of progestin-containing
oral contraceptives may suppress the growth of premalignant cells in the
ovarian cortex, thus protecting against ovarian cancer.4
There are, however, major obstacles that limit the clinical use of
progestins in ovarian cancer. Foremost, ovarian cancer is a
heterogeneous disease that consists of etiologically distinct tumors
that share an anatomical site. Consequently, progestin sensitivity is
likely restricted to certain histological types, such endometrioid and
serous cancers.4
Further, PR as well as FOXO1 are frequently lost in ovarian cancer; the
robustness of the senescence response in vivo has not yet been studied,
and the contribution of putative non-genomic progestin receptors in
modulating cellular responses to hormonal therapies remains poorly
understood and controversial.5........
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.